These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 30747066)

  • 1. Anti-cancer Effects of Curcumin on Myelodysplastic Syndrome through the Inhibition of Enhancer of Zeste Homolog-2 (EZH2).
    Ma L; Zhang X; Wang Z; Huang L; Meng F; Hu L; Chen Y; Wei J
    Curr Cancer Drug Targets; 2019; 19(9):729-741. PubMed ID: 30747066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome.
    Hasegawa N; Oshima M; Sashida G; Matsui H; Koide S; Saraya A; Wang C; Muto T; Takane K; Kaneda A; Shimoda K; Nakaseko C; Yokote K; Iwama A
    Leukemia; 2017 Apr; 31(4):861-871. PubMed ID: 27694924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling.
    Khan H; Ni Z; Feng H; Xing Y; Wu X; Huang D; Chen L; Niu Y; Shi G
    Phytomedicine; 2021 Oct; 91():153706. PubMed ID: 34517264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered EZH2 splicing and expression is associated with impaired histone H3 lysine 27 tri-Methylation in myelodysplastic syndrome.
    Shirahata-Adachi M; Iriyama C; Tomita A; Suzuki Y; Shimada K; Kiyoi H
    Leuk Res; 2017 Dec; 63():90-97. PubMed ID: 29127861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
    Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
    J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.
    Yang L; Ma DW; Cao YP; Li DZ; Zhou X; Feng JF; Bao J
    Theranostics; 2021; 11(8):3742-3759. PubMed ID: 33664859
    [No Abstract]   [Full Text] [Related]  

  • 8. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
    He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
    J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The KDM2B- let-7b -EZH2 axis in myelodysplastic syndromes as a target for combined epigenetic therapy.
    Karoopongse E; Yeung C; Byon J; Ramakrishnan A; Holman ZJ; Jiang PY; Yu Q; Deeg HJ; Marcondes AM
    PLoS One; 2014; 9(9):e107817. PubMed ID: 25225797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant Expression of
    de Souza Fernandez T; Fonseca Alvarenga T; Almeida Antônio de Kós E; Lamim Lovatel V; Tavares RC; da Costa ES; de Souza Fernandez C; Abdelhay E
    Biomed Res Int; 2019; 2019():3176565. PubMed ID: 31886200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Epigenetic dysregulation in myelodysplastic syndromes].
    Sashida G
    Rinsho Ketsueki; 2017; 58(10):1809-1817. PubMed ID: 28978819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect and Mechanism of Curcumin on EZH2 - miR-101 Regulatory Feedback Loop in Multiple Myeloma.
    Wu C; Ruan T; Liu W; Zhu X; Pan J; Lu W; Yan C; Tao K; Zhang W; Zhang C
    Curr Pharm Des; 2018; 24(5):564-575. PubMed ID: 28322158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AGE-Induced Suppression of EZH2 Mediates Injury of Podocytes by Reducing H3K27me3.
    Liebisch M; Wolf G
    Am J Nephrol; 2020; 51(9):676-692. PubMed ID: 32854097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring.
    Xu F; Li X; Wu L; Zhang Q; Yang R; Yang Y; Zhang Z; He Q; Chang C
    Ann Hematol; 2011 Jun; 90(6):643-53. PubMed ID: 21125401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas.
    Lue JK; Prabhu SA; Liu Y; Gonzalez Y; Verma A; Mundi PS; Abshiru N; Camarillo JM; Mehta S; Chen EI; Qiao C; Nandakumar R; Cremers S; Kelleher NL; Elemento O; Amengual JE
    Clin Cancer Res; 2019 Sep; 25(17):5271-5283. PubMed ID: 30979734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1.
    Wu GQ; Chai KQ; Zhu XM; Jiang H; Wang X; Xue Q; Zheng AH; Zhou HY; Chen Y; Chen XC; Xiao JY; Ying XH; Wang FW; Rui T; Liao YJ; Xie D; Lu LQ; Huang DS
    Oncotarget; 2016 May; 7(18):26535-50. PubMed ID: 27049834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
    Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
    Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanoformulation of EPZ011989 Attenuates EZH2-c-Myb Epigenetic Interaction by Proteasomal Degradation in Acute Myeloid Leukemia.
    Kaundal B; Srivastava AK; Dev A; Mohanbhai SJ; Karmakar S; Roy Choudhury S
    Mol Pharm; 2020 Feb; 17(2):604-621. PubMed ID: 31904978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK/ERK and PI3K/AKT pathway inhibitors affect the transformation of myelodysplastic syndrome into acute myeloid leukemia via H3K27me3 methylases and de‑methylases.
    Zheng Z; Chen X; Zhang Y; Ren F; Ma Y
    Int J Oncol; 2023 Dec; 63(6):. PubMed ID: 37921060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.